抗白介素2受体单克隆抗体治疗移植肾难治性排斥反应

Anti-interleukin-2 receptor monoclonal in the treatment of refractory acute rejection after renal transplantation

为了提高抗移植肾难治性排斥反应的效果，对肾移植术后急性难治性排斥反应１１例（其中２例为急性加速性排斥反应），应用抗白介素２受体单克隆抗体（抗Ｔａｃ）治疗，９例（包括１例急性加速性排斥反应）完全逆转，逆转率８１．８％。结果显示：抗Ｔａｃ特异性强、反应灵敏、安全有效、副作用小，就抗Ｔａｃ治疗急性排斥反应（ＡＲ）的机理及治疗难治性ＡＲ的应用价值进行讨论。

patients suffered from refractory acute rejecion of the renal transplant (including 2 episodes of acute accelerate rejection)were treated with anti-interleukin-2 receptor monoclonal (anti-Tac). 8 acute rejection and 1 accelerate rejection episodes have been completely reversed, the reverse rate being 81. 8%.Anti-Tac is highly specific, safe, effective and with least side effect. The mechanism of anti-Tac in the treatment of refractory acute rejection of renal transplant was discussed.